Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of Empagliflozin on cardiac structure,
function and circulating biomarkers in patients with Type II diabetes. Empagliflozin
(anti-hyperglycemic agent), approved by Health Canada and the FDA for the treatment of Type
II diabetes, demonstrated a reduction in cardiovascular deaths and heart failure from a
previous post-marketing clinical trial. The use of empagliflozin to treat patients with
diabetes and heart disease has been approved by Health Canada. However, the process by which
it may give this beneficial effect remains unclear and needs further investigation.
Therefore, the aim of this study is to provide a fundamental understanding of the mechanistic
basis by which Empagliflozin could provide its potential cardio-protective effects by
employing the use of Cardiac Magnetic Resonance Imaging (CMRI).
Phase:
Phase 4
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto